+

WO2019038361A1 - Medicaments for the treatment of vasoconstriction related diseases or disorders - Google Patents

Medicaments for the treatment of vasoconstriction related diseases or disorders Download PDF

Info

Publication number
WO2019038361A1
WO2019038361A1 PCT/EP2018/072735 EP2018072735W WO2019038361A1 WO 2019038361 A1 WO2019038361 A1 WO 2019038361A1 EP 2018072735 W EP2018072735 W EP 2018072735W WO 2019038361 A1 WO2019038361 A1 WO 2019038361A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
tetramethylchroman
carboxamide
sul
methanone
Prior art date
Application number
PCT/EP2018/072735
Other languages
French (fr)
Inventor
Robert Henk Henning
Gerrit Jan Willem Euverink
Guido Krenning
Adrianus Cornelis Van Der Graaf
Original Assignee
Sulfateq B.V.
Rijksuniversiteit Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq B.V., Rijksuniversiteit Groningen filed Critical Sulfateq B.V.
Priority to EP18769288.4A priority Critical patent/EP3672593B1/en
Priority to US16/640,785 priority patent/US12156862B2/en
Priority to ES18769288T priority patent/ES3013118T3/en
Publication of WO2019038361A1 publication Critical patent/WO2019038361A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions.
  • Vasoconstriction related disorder comprise a group of disorders, like for example pulmonary hypertension, portal hypertension, vasospastic diseases, Raynaud's disease, acrocyanosis, livedo reticularis, post-traumatic dystrophy, occlusive diseases associated with inflammation and Buerger's disease.
  • Vasoconstriction is the process of constriction of blood vessels, which may result in decrease of flow of blood.
  • Normal blood flow is necessary for carrying oxygenated blood to all parts of the body and when the normal flow is disrupted it may cause various problems.
  • Vasoconstriction can occur due to medical condition or due to psychological disorder. This condition happens when the small muscles of the walls constrict causing narrowing of blood vessels. Actually this process is exactly opposite condition of vaso-dilation in which the blood vessels enlarge or open widely. The contraction of blood vessels can increase the heat of the body and may cause vascular conflict. Following this condition, the skin becomes paler than before since blood supply is drastically reduced. It occurs mostly on large arteries thus obstructing the blood flow but sometimes it can develop on small arterioles causing constriction of blood vessels.
  • alpha adrenoreceptor antagonist (which is a vasodilator) can be administered for reducing the constriction of blood vessels and increasing blood flow. Treating the problem with calcium channel blockers would facilitate widening of blood vessels.
  • the 5 main categories of drugs used in the initial treatment of hypertensive vascular diseases are (1). diuretics, (2). beta-adrenergic blockers, (3). calcium channel blockers, (4). angiotensin-converting enzyme (ACE) inhibitors, and (5). angiotensin receptor blockers (ARBs).
  • ACE angiotensin-converting enzyme
  • ARBs angiotensin receptor blockers
  • antihypertensive agents is roughly equally effective, producing a good antihypertensive response in 40% to 60% of cases.
  • vasoconstriction related disorders in particular ones that have less side effects, or preferably no side effects at all in the dosing range of such compound. It is an object of the present invention to provide compounds for the treatment of vasoconstriction related disorders or conditions.
  • chromanol compounds have been described in e.g. WO2014/098586, WO2015/193365 and WO2016/188766. These compounds show a wide variety of protective effects on cells and organs.
  • the compounds described in detail are developed by Sulfateq, and have abbreviations, referring to SUL-XXX (XXX being a 2 or 3 digit number). Many of these compounds are racemic mixtures, although some enantiomers have been tested as well.
  • the present invention relates to the (2R) enantiomeric form of a 6-chromanol derivative wherein the 6-chromanol derivative is chosen from the group consisting of (6-hydroxy- 2,5,7, 8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone (SUL- 121); (6-hydroxy-2,5,7,8- tetramethylchroman-2-yl)(morpholino)methanone (SUL-95); N-(benzyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide (SUL-96), N-(4-fluorobenzyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide (SUL-97); 6-hydroxy-N-((S)-2-hydroxy-l-phenylethyl)- 2,5,7, 8-tetramethylchroman-2-carboxamide (SUL-98); N-(phenyl)-6-hydroxy-2,5,
  • the chromanol compound is chosen from the group consisting of the 2R enantiomer of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l- yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; - N-(phenyl)-6- hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamido)benzoate; and pharmaceutically acceptable salts thereof.
  • the chromanol compound is chosen from the group consisting of the 2R enantiomer of (6-hydroxy-2,5,7,8-tetramethylchroman-2- yl)(morpholino)methanone, and (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l- yl)methanone.
  • the present invention relates to the (R) enantiomeric form of a 6-chromanol derivative, wherein said 6-chromanol derivative is (R)(6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone and pharmaceutically acceptable salts thereof.
  • the present invention relates to the (R) enantiomeric form of a 6-chromanol derivative as described, wherein the vasoconstriction related disorder is selected from the group consisting of pulmonary hypertension, portal hypertension, vasospastic diseases, Raynaud's disease, acrocyanosis, livedo reticularis, posttraumatic dystrophy, occlusive diseases associated with inflammation, (pre)eclampsia, and Buerger's disease.
  • Pulmonary hypertension in particular relates to pulmonary arterial hypertension, for which the present invention is preferred.
  • Another disorder that can be treated with the described compounds is cardiac hypertrophy and fibrosis.
  • the vasoconstriction disorder particularly relates to al adrenoceptor mediated disorders, such as pulmonary arterial hypertension and cardiac hypertrophy and fibrosis.
  • HFpEF preserved ejection fraction
  • the vasoconstrictive disorder has a co-indication of inflammation.
  • the chromanol compounds are effective as anti-inflammatory agents, the use of said chromanol compounds is very effective in the prophylaxis or treatment of vasoconstrictive and inflammation related disorders, such as pulmonary hypertension, portal hypertension and
  • SUL-121 is a 1: 1 racemic mixture of two enantiomers (S enantiomer named SUL-
  • SUL-150 R enantiomer named SUL-150.
  • PE phenylephrine
  • the present invention relates to the (R) enantiomeric form of a 6-chromanol derivative, wherein said prophylaxis or treatment of vasoconstriction related disorders or conditions is mediated by inhibition of the al adrenoceptor, ai adrenoceptors are coupled with the G-protein (GPRC), specifically G q and Gn subtypes.
  • GPRC G-protein
  • Their activation leads to a downstream activation of phospholipase pathways, increase of (Ca 2+ )i and a subsequent constriction of the vascular smooth muscle.
  • EGFR Epidermal Growth Factor Receptor
  • SUL-150 inhibits vasoconstriction is via direct interaction with the ai adrenoceptor as a receptor antagonist.
  • SUL-151 did not affect calcium transients in any of the investigated al adrenoceptor subtypes.
  • Results indicate that SUL- 150 is capable of counteracting vascular constriction and intracellular calcium responses specifically via its action on ai adrenoceptors.
  • Radiolabeled prazosin displacement suggests that SUL-150 competitively binds to the antagonist binding site.
  • Prazosin is an ⁇ -blocker which acts as an inverse agonist at alpha- 1 adrenergic receptors.
  • SUL-150 conveys a range of additional beneficial effects.
  • Combined anti-oxidant, anti-inflammatory and vasodilatory properties of SUL-150 may be applicable in the treatment of diseases related to vasoconstriction, such as Raynaud's disease.
  • the present invention relates to (R)(6-hydroxy- 2,5,7, 8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone, and to the use of said compound and pharmaceutically acceptable salts thereof as a medicament.
  • the present invention relates to the 2R-6- chromanol derivative, wherein the prophylaxis or treatment of vasoconstriction related disorders or conditions is mediated by inhibition of the al adrenoceptor.
  • the compounds are preferably used in effective amounts, to achieve a vasodilatory effect. Effects are observed with amounts of 1 ⁇ , but preferably higher amounts are used.
  • Preferred amounts are concentrations in vivo or in vitro of about 10 ⁇ or higher, more preferably about 20 ⁇ or higher. Generally, a concentration in human of about 200 ⁇ or lower should be sufficient and safe.
  • dosage forms of about 20 mg or more, preferably 50 mg or more, preferably 100 mg or more are suitable.
  • solid, oral dosage forms contain as a maximum about 500 mg compound, preferably about 450 mg or less, to allow for excipients. With i.v. other liquid forms of administration, larger amounts can be administered.
  • Examples of dosages which can be used are an effective amount of the compounds of the invention of a dosage of 0.2 mg kg or higher, such as preferably within the range of about 1 mg /kg to about 100 mg/kg, or within about 2 mg /kg to about 40 mg/kg body weight, or within about 3 mg/kg to about 30 mg/kg body weight, or within about 4 mg /kg to about 15mg/kg body weight.
  • Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided dosage of two, three or four times daily.
  • the compounds described herein can be formulated as pharmaceutical compositions by formulation with additives such as pharmaceutically or physiologically acceptable excipients carriers, and vehicles.
  • suitable pharmaceutically or physiologically acceptable excipients, carriers and vehicles include processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidinone, low melting waxes, and the like, as well as combinations of any two or more thereof.
  • processing agents and drug delivery modifiers and enhancers such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl-P-cyclodextrin
  • a pharmaceutical composition can comprise a unit dose formulation, where the unit dose is a dose sufficient to have an vasodilatory effect, preferably a vasodilatory therapeutic effect.
  • the unit dose may be a dose administered periodically in a course of treatment or suppression of a vasodilatory disorder.
  • compositions containing the compounds of the invention may be in any form suitable for the intended method of administration, including, for example, a solution, a suspension, or an emulsion.
  • Liquid carriers are typically used in preparing solutions, suspensions, and emulsions.
  • Liquid carriers contemplated for use in the practice of the present invention include, for example, water, saline, pharmaceutically acceptable organic solvent(s),
  • the liquid carrier may contain other suitable pharmaceutically acceptable additives such as solubilizers, emulsifiers, nutrients, buffers, preservatives, suspending agents, thickening agents, viscosity regulators, stabilizers, and the like.
  • suitable organic solvents include, for example, monohydric alcohols, such as ethanol, and polyhydric alcohols, such as glycols.
  • Suitable oils include, for example, soybean oil, coconut oil, olive oil, safflower oil, cottonseed oil, and the like.
  • the carrier can also be an oily ester such as ethyl oleate, isopropyl myristate, and the like.
  • Compositions of the present invention may also be in the form of microparticles, microcapsules, liposomal encapsulates, and the like, as well as combinations of any two or more thereof.
  • Time-release or controlled release delivery systems may be used, such as a diffusion controlled matrix system or an erodible system, as described for example in: Lee,
  • the matrix may be, for example, a biodegradable material that can degrade spontaneously in situ and in vivo for, example, by hydrolysis or enzymatic cleavage, e.g. , by proteases.
  • the delivery system may be, for example, a naturally occurring or synthetic polymer or copolymer, for example in the form of a hydrogel.
  • Exemplary polymers with cleavable linkages include polyesters, polyorthoesters, polyanhydrides, polysaccharides, poly(phosphoesters), poly amides, polyurethanes, poly(imidocarbonates) and poly(phosphazenes ).
  • the compounds of the invention may be administered enterally, orally, parenterally, sublingually, by inhalation (e. g. as mists or sprays), rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically or physiologically acceptable carriers, adjuvants, and vehicles as desired.
  • suitable modes of administration include oral, subcutaneous, transdermal, transmucosal, iontophoretic, intravenous, intraarterial, intramuscular, intraperitoneal, intranasal (e. g. via nasal mucosa), subdural, rectal, gastrointestinal, and the like, and directly to a specific or affected organ or tissue.
  • Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
  • the compounds are mixed with pharmaceutically acceptable carriers, adjuvants, and vehicles appropriate for the desired route of administration.
  • Oral administration is a preferred route of administration, and formulations suitable for oral administration are preferred formulations.
  • the compounds described for use herein can be administered in solid form, in liquid form, in aerosol form, or in the form of tablets, pills, powder mixtures, capsules, granules, injectables, creams, solutions, suppositories, enemas, colonic irrigations, emulsions, dispersions, food premixes, and in other suitable forms.
  • the compounds can also be administered in liposome formulations.
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in propylene glycol.
  • a nontoxic parenterally acceptable diluent or solvent for example, as a solution in propylene glycol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols that are solid at room temperature but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • a suitable nonirritating excipient such as cocoa butter and polyethylene glycols that are solid at room temperature but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch.
  • Such dosage forms may also comprise additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
  • Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents.
  • the invention also provides articles of manufacture and kits containing materials useful for treating, preventing, or suppressing symptoms associated with vasodilatory related conditions or disorders.
  • the article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition having an active agent which is effective for treating, preventing, or suppressing symptoms associated with a vasodilatory disorder or with a condition associated with vasodilatory dysfunction.
  • the active agent in the composition is one or more of the compounds of the invention.
  • the label on the container preferably indicates that the composition is used for treating, preventing, or suppressing symptoms associated with a vasodilatory related disorder or condition, and may also indicate directions for either in vivo or in vitro use, such as those described above.
  • kits comprising any one or more of the compounds of the invention.
  • the kit of the invention comprises the container described above.
  • the kit of the invention comprises the container described above and a second container comprising a buffer. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host to which the active ingredient is administered and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, body area, body mass index (BMI), general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the type, progression, and severity of the particular disease undergoing therapy or condition to be treated.
  • the unit dosage chosen is usually fabricated and administered to provide a defined final concentration of drug in the blood, tissues, organs, or other targeted region of the body. The effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician or skilled person.
  • Figure 1 Shows the constriction responses to phenylephrine (PE) in the presence of different doses of SUL-150 (B) and SUL-151 (C). Methoxamine-induced vasoconstriction was measured with intact endothelium (D) and endothelium-denuded rings (E) in the presence of vehicle (0.1% DMSO) and two dosages (30 ⁇ and ⁇ ) of
  • Figure 2 Shows constriction responses to histamine (A) and the thromboxane agonist
  • Figure 3 Shows constriction responses to phenylephrine in the presence of vehicle and three concentrations of the EGFR inhibitor AG1478 (A) and 20 ⁇ AG1478 with 50 ⁇ SUL-150 (B).
  • Figure 4 Shows intracellular calcium measurements in transgenic CHO cells overexpressing
  • Figure 5 Shows displacement of tritium-labelled prazosin by SUL-150 and SUL-151 in di A
  • FIG. 6 Shows the structural formula of the SUL-121 ((6-hydroxy-2,5,7,8- tetramethylchroman-2-yl)-(piperaziniyl)-methanone) compound.
  • SUL-121 is a racemic 1: 1 mixture of (R)-enantiomer SUL-150 and (S)-enantiomer SUL-151.
  • the * indicates the chiral centre of SUL-121 in the structural formula, which is at the 2 position in the chromanol group. Therefore, generally, the group of enantiomers is named the "2-R enantiomer of.
  • Porcine kidneys were obtained from a local slaughterhouse (Kroon Vlees, Gotenburgweg 30, 9723 TM Groningen, The Netherlands) and transported on ice in normal physiological Krebs buffer containing 120 mM NaCl, 6 mM KCl, 2.5 mM CaCl 2 x 2H 2 0, 1.2 mM MgCl 2 x 6H 2 0, 1.2 mM NaH 2 P0 4 x H 2 0, 25 mM NaHC0 3 and 11.4 mM D-(+)-Glucose monohydrate (all ingredients were purchased from Merck) in ultrapure water.
  • the renal artery tree was dissected from the kidney, cleaned of surrounding connective tissue and cut into equally-sized ring segments (2 mm in length). In some rings, endothelium denudation was performed by gentle rubbing of the intimal surface with a paper clip. Rings were mounted in organ baths as described previously (Buikema et al., 2000). Arterial rings were washed thoroughly by replacing Krebs buffer and allowed to equilibrate for a period of 60 min under 1.4g of resting tension before they were assessed for viability by inducing 2 subsequent constrictions with KCl (60mM). Rings that failed to produce a threshold increase in diameter of ⁇ were excluded. After washout and stabilization, rings were treated for 30 minutes by incubation with vehicle (0.1% DMSO), SUL-121, SUL-150 or SUL-151, followed by subsequent incubation with cumulative doses of phenylephrine.
  • vehicle (0.1% DMSO
  • SUL-121, SUL-150 or SUL-151 followed
  • Cell culture CHO-K1 cells were stably transfected with a plasmid containing human al-AR subtypes A, B and D in separate cell lines in DMEM-F12 medium with 10% FBS, 1% penicillin- streptomycin and 200 g/mL Geneticin (G418, Invitrogen, Carlsbad, CA).
  • HeLa cells endogenously expressing histamine and TP receptors were grown in DMEM-F12 medium enriched with 10% FBS and 1% penicillin-streptomycin. Cells were kept in a tissue culture incubator at 37°C in 5% 0 2 / 95% C0 2 atmosphere and grown in 75cm 2 non-treated cell culture flasks. Plating was performed 24 hours before measurement on black transparent- bottom 96-well plates at 20,000 cells per well density.
  • Example 3 Example 3:
  • CHO cells were treated with either vehicle (0.1% DMSO) or SUL-121 enantiomers for 30 min at 37°C and stimulated with a 3-fold dilution series of PE (20 ⁇ - ⁇ ).
  • [Ca 2+ ]i was measured using the fluorescent FLIPR Calcium 6 assay kit (Molecular Devices) in immortalized CHO cells stably expressing the ⁇ adrenoceptor.
  • the "Vehicle” used in all experiments is 0.1% DMSO solution.
  • Vascular constriction responses are expressed as percentage of final response to KC1. Data are expressed as mean + SEM. *p ⁇ 0.05.
  • the primary sequence of di A adrenoceptor was obtained from UniProt database (The UniProt Consortium, 2017) using reference code P35348 and uploaded to SWISS-MODEL in order to build a homology model, resulting in 373 templates. Subsequently, template ligand codes were used to query the PDB database to obtain structural data in SMILES format, which were processed by Chemmine to detect similarities with SUL-150.
  • the SWISS-MODEL template that contained a ligand with the highest similarity score (a D3 dopamine receptor in complex with, Eticlopride, ETQ) was used to align the di A -AR sequence onto a modelled backbone.
  • the resulting homology model was validated by Ramachandran plot and prepared with Protein Preparation Wizard by the addition of hydrogens, bond order assignment, generation of partial charges to heteroatoms and disulfide bonds. Final refinement was performed by hydrogen bond assignment at pH 7.4 and restrained minimization at 0.3 RMSD.
  • Prazosin, SUL-150 and SUL-151 structural files were converted from SMILES to 3D structures using LigPrep. Protonation states were generated with Epik at pH 7.4 and small molecule energy parameters were computed using OPLS3 forcefield.
  • Table 1 LogECso values of phenylephrine-induced constriction responses in the presence
  • Table 2 LogECso values of histamine and U46619-induced constriction responses in the presence of SUL-150.
  • SUL-150 are upstream of calcium. We therefore explored whether SUL-150 could directly interact with the ai adrenoceptor as a receptor antagonist. For this, a displacement binding assay was performed on the (Xi A adrenoceptor transgenic CHO cells using radiolabeled prazosin, an established (Xi A adrenoceptor antagonist. SUL- 150 was more potent in displacing the radioligand compared to SUL-151, which displaced [7-Methoxy-3H]-prazosin only at concentrations higher than 10 ⁇ (Figure 5).
  • Prazosin coexists in two protonation forms at pH 7.4.
  • the Nl assumes a positive charge, subsequently forming a salt bridge with the negatively charged side chain of ASP106, ultimately causing this form to assume an inverted orientation relative to its non- protonated form.
  • the quinazoline scaffold of non-protonated prazosin was docked close to TM5 to form a confocal hydrogen bond between the 6,7-methoxy groups and SER188, a hydrogen bond between furan oxygen and SER83, and between prazosin carboxamide and GLN177 side chain; van der Waals interactions with side chains of PHE86, VAL107, ILE178, PHE289, MET292, and PHE312; ⁇ - ⁇ interactions with PHE288 and PHE312; and a ⁇ -hydrogen bond interaction with the side chain carboxy group and backbone peptide carboxamide of ASP106.
  • the proposed binding mode of non-protonated prazosin indicated interactions which were in accord with those described in the literature.
  • SUL-150 and SUL-151 demonstrated alignment of the chromane scaffold with prazosin quinazoline, 6-hydroxy groups (SUL) and 6-metoxy (prazosin) as well as over their common piperazine moiety.
  • Residues which were involved in forming contacts with all three compounds were VAL107, ILE178, SER188, PHE288, PHE289.
  • Glide scores computed using the Schrodinger Small-Drug Discovery Suite were - 10.8 kcalxmol "1 , -10.2 kcalxmol 1 and -9.4 kcalxmol 1 for prazosin, SUL-150 and SUL-151 respectively.
  • Prazosin and SUL-150 formed contacts with PHE312 and ASP106 confirmed in prazosin binding by mutagenesis, whereas SUL-151 did not show interactions with these residues. Additionally, the chirality of SUL-150 enables the orientation of its carboxamide towards ASN179, effectively forming a hydrogen bond. Additional hydrogen bond was formed between its protonated N- terminal and TYR316.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone; N-(benzyl)-6-hydroxy- 2,5,7, 8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.

Description

MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED
DISEASES OR DISORDERS
DESCRIPTION
The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions.
Vasoconstriction related disorder comprise a group of disorders, like for example pulmonary hypertension, portal hypertension, vasospastic diseases, Raynaud's disease, acrocyanosis, livedo reticularis, post-traumatic dystrophy, occlusive diseases associated with inflammation and Buerger's disease.
Vasoconstriction is the process of constriction of blood vessels, which may result in decrease of flow of blood. Normal blood flow is necessary for carrying oxygenated blood to all parts of the body and when the normal flow is disrupted it may cause various problems.
Vasoconstriction can occur due to medical condition or due to psychological disorder. This condition happens when the small muscles of the walls constrict causing narrowing of blood vessels. Actually this process is exactly opposite condition of vaso-dilation in which the blood vessels enlarge or open widely. The contraction of blood vessels can increase the heat of the body and may cause vascular conflict. Following this condition, the skin becomes paler than before since blood supply is drastically reduced. It occurs mostly on large arteries thus obstructing the blood flow but sometimes it can develop on small arterioles causing constriction of blood vessels.
An alpha adrenoreceptor antagonist (which is a vasodilator) can be administered for reducing the constriction of blood vessels and increasing blood flow. Treating the problem with calcium channel blockers would facilitate widening of blood vessels.
Control of hypertension in the vascular patient is clearly a priority. However, these patients often will have significant co-morbidities that may influence the choice of medication. The 5 main categories of drugs used in the initial treatment of hypertensive vascular diseases are (1). diuretics, (2). beta-adrenergic blockers, (3). calcium channel blockers, (4). angiotensin-converting enzyme (ACE) inhibitors, and (5). angiotensin receptor blockers (ARBs). Each of the
antihypertensive agents is roughly equally effective, producing a good antihypertensive response in 40% to 60% of cases. Some antihypertensives, especially ACE and ARBs, also may have beneficial effects on the vascular and metabolic systems separate from their blood pressure lowering effects, which suggests they may be beneficial even if blood pressure is well maintained with other agents.
However, there remains a need for new compounds for treatment of vasoconstriction related disorders, in particular ones that have less side effects, or preferably no side effects at all in the dosing range of such compound. It is an object of the present invention to provide compounds for the treatment of vasoconstriction related disorders or conditions.
The above object is met by the present invention by the (2R) enantiomeric form of certain 6-chromanol derivatives for use in the treatment of vasoconstriction related disorders or conditions.
Certain chromanol compounds have been described in e.g. WO2014/098586, WO2015/193365 and WO2016/188766. These compounds show a wide variety of protective effects on cells and organs. The compounds described in detail are developed by Sulfateq, and have abbreviations, referring to SUL-XXX (XXX being a 2 or 3 digit number). Many of these compounds are racemic mixtures, although some enantiomers have been tested as well.
Unexpectedly, upon further research, a number of the SUL compounds showed reversal effects of vascular constriction, which effect is useful in the treatment of vasoconstriction related disorders.
Thus, the present invention relates to the (2R) enantiomeric form of a 6-chromanol derivative wherein the 6-chromanol derivative is chosen from the group consisting of (6-hydroxy- 2,5,7, 8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone (SUL- 121); (6-hydroxy-2,5,7,8- tetramethylchroman-2-yl)(morpholino)methanone (SUL-95); N-(benzyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide (SUL-96), N-(4-fluorobenzyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide (SUL-97); 6-hydroxy-N-((S)-2-hydroxy-l-phenylethyl)- 2,5,7, 8-tetramethylchroman-2-carboxamide (SUL-98); N-(phenyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide (SUL- 103); 6-hydroxy-2,5,7,8-tetramethyl-N-(2- nitrophenyl)chroman-2-carboxamide (SUL- 104); 6-hydroxy-2,5,7,8-tetramethyl-N-(3- nitrophenyl)chroman-2-carboxamide (SUL- 105); N-(4-fluorophenyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide (SUL-106); methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman- 2-carboxamido)benzoate (SUL-107); N-( (R)-2-amino-2-oxo-l-phenylethyl)-6-hydroxy-2,5, 7,8- tetramethylchroman-2-carboxamide (SUL-111); (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)((S)- 2-(hydroxymethyl )pyrrolidin-l-yl )methanone (SUL-112); 2-(((4-fluorobenzyl)amino)mefhyl)- 2,5,7, 8-tetramethylchroman-6-ol (SUL-116); 2-(((S)-2-(hydroxymethyl)pyrrolidin-l-yl)methyl)- 2,5,7, 8-tetramethylchroman-6-ol (SUL- 128); 2-((((S)-2-hydroxy-l-phenylethyl)amino)methyl)- 2,5,7,8-tetramethvlchroman-6-ol (SUL-129); 2-(((S)-2-(hydroxymethyl)pyrrolidin-l-yl)methyl)- 2,5,7, 8-tetramethvlchroman-6-ol (SUL- 134); 2-(((R-2-(hydroxymethyl)pyrrolidin-l-yl)methyl)- 2,5,7, 8-tetramethylchroman-6-ol (SUL135); ( 6-hydroxy-5, 7-diisopropyl-2,8-dimethylchroman-2- yl)(piperazin-l-yl)methanone (SUL-137); l-( 6-hydroxy-2,5, 7 ,8-tetramethylchroman-2-carbonyl )-pyrrolidine-S-2-carboxvlic acid (SUL-143) and pharmaceutically acceptable salts thereof.
In a preferred embodiment, the chromanol compound is chosen from the group consisting of the 2R enantiomer of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l- yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; - N-(phenyl)-6- hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamido)benzoate; and pharmaceutically acceptable salts thereof.
In another particularly preferred embodiment, the chromanol compound is chosen from the group consisting of the 2R enantiomer of (6-hydroxy-2,5,7,8-tetramethylchroman-2- yl)(morpholino)methanone, and (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l- yl)methanone.
According to a most preferred embodiment, the present invention relates to the (R) enantiomeric form of a 6-chromanol derivative, wherein said 6-chromanol derivative is (R)(6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone and pharmaceutically acceptable salts thereof.
According to yet another preferred embodiment, the present invention relates to the (R) enantiomeric form of a 6-chromanol derivative as described, wherein the vasoconstriction related disorder is selected from the group consisting of pulmonary hypertension, portal hypertension, vasospastic diseases, Raynaud's disease, acrocyanosis, livedo reticularis, posttraumatic dystrophy, occlusive diseases associated with inflammation, (pre)eclampsia, and Buerger's disease. Pulmonary hypertension in particular relates to pulmonary arterial hypertension, for which the present invention is preferred. Another disorder that can be treated with the described compounds is cardiac hypertrophy and fibrosis.
The vasoconstriction disorder particularly relates to al adrenoceptor mediated disorders, such as pulmonary arterial hypertension and cardiac hypertrophy and fibrosis.
Another indication which is preferably treated with the compounds of the present invention is heart failure with preserved ejection fraction (HFpEF), in which hypertension generally is co-indicated.
In a preferred embodiment, the vasoconstrictive disorder has a co-indication of inflammation. As the chromanol compounds are effective as anti-inflammatory agents, the use of said chromanol compounds is very effective in the prophylaxis or treatment of vasoconstrictive and inflammation related disorders, such as pulmonary hypertension, portal hypertension and
(pre)eclampsia.
SUL-121 is a 1: 1 racemic mixture of two enantiomers (S enantiomer named SUL-
151, R enantiomer named SUL-150). The effects of SUL-150 and SUL-151 on phenylephrine (PE) -induced vascular constrictions were investigated. The results showed that whereas SUL-150 exerted a dose-dependent increase of EC50, whereas no significant effects after treatment with SUL-151 were observed. The SUL-150 was able to inhibit or counteract the induced vascular constrictions. According to a preferred embodiment, the present invention relates to the (R) enantiomeric form of a 6-chromanol derivative, wherein said prophylaxis or treatment of vasoconstriction related disorders or conditions is mediated by inhibition of the al adrenoceptor, ai adrenoceptors are coupled with the G-protein (GPRC), specifically Gq and Gn subtypes. Their activation leads to a downstream activation of phospholipase pathways, increase of (Ca2+)i and a subsequent constriction of the vascular smooth muscle. Additionally, we have demonstrated the ability of ai adrenoceptors to trans-activate the Epidermal Growth Factor Receptor (EGFR) which contributes to downstream phosphorylation of extracellular signal-regulated kinases 1 and 2. The inhibition of EGFR attenuated constriction responses to PE in isolated rat aortas. Therefore, we investigate the effects of SUL-150 on the mechanism of EGFR transactivation by al
adrenoceptors.
It was found that the mechanism through which SUL-150 inhibits vasoconstriction is via direct interaction with the ai adrenoceptor as a receptor antagonist. SUL-151 did not affect calcium transients in any of the investigated al adrenoceptor subtypes. Results indicate that SUL- 150 is capable of counteracting vascular constriction and intracellular calcium responses specifically via its action on ai adrenoceptors. Radiolabeled prazosin displacement suggests that SUL-150 competitively binds to the antagonist binding site. Prazosin is an αι-blocker which acts as an inverse agonist at alpha- 1 adrenergic receptors. Compared with prazosin, SUL-150 conveys a range of additional beneficial effects. Combined anti-oxidant, anti-inflammatory and vasodilatory properties of SUL-150 may be applicable in the treatment of diseases related to vasoconstriction, such as Raynaud's disease.
The present invention, according to a further aspect, relates to (R)(6-hydroxy- 2,5,7, 8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone, and to the use of said compound and pharmaceutically acceptable salts thereof as a medicament.
According to preferred embodiment, the present invention relates to the 2R-6- chromanol derivative, wherein the prophylaxis or treatment of vasoconstriction related disorders or conditions is mediated by inhibition of the al adrenoceptor.
The compounds are preferably used in effective amounts, to achieve a vasodilatory effect. Effects are observed with amounts of 1 μΜ, but preferably higher amounts are used.
Preferred amounts are concentrations in vivo or in vitro of about 10 μΜ or higher, more preferably about 20 μΜ or higher. Generally, a concentration in human of about 200 μΜ or lower should be sufficient and safe.
For human use, this would mean - assuming a 30 L distribution volume, 100% availability and a concentration of about 1 μΜ - a dosage of about 10 mg or more. Preferred amounts would result in a concentration of about 10 μΜ - for which a dosage of about 100 mg or more would be suitable. Hence, preferably, dosage forms of about 20 mg or more, preferably 50 mg or more, preferably 100 mg or more are suitable. Generally, solid, oral dosage forms contain as a maximum about 500 mg compound, preferably about 450 mg or less, to allow for excipients. With i.v. other liquid forms of administration, larger amounts can be administered.
Examples of dosages which can be used are an effective amount of the compounds of the invention of a dosage of 0.2 mg kg or higher, such as preferably within the range of about 1 mg /kg to about 100 mg/kg, or within about 2 mg /kg to about 40 mg/kg body weight, or within about 3 mg/kg to about 30 mg/kg body weight, or within about 4 mg /kg to about 15mg/kg body weight. Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided dosage of two, three or four times daily.
The compounds described herein can be formulated as pharmaceutical compositions by formulation with additives such as pharmaceutically or physiologically acceptable excipients carriers, and vehicles. Suitable pharmaceutically or physiologically acceptable excipients, carriers and vehicles include processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl-P-cyclodextrin, polyvinylpyrrolidinone, low melting waxes, and the like, as well as combinations of any two or more thereof. Other suitable pharmaceutically acceptable excipients are described in "Remington's Pharmaceutical Sciences, " Mack Pub. Co. , New Jersey (1991), and "Remington: The Science and Practice of Pharmacy, " Lippincott Williams & Wilkins, Philadelphia, 20th edition (2003) and 21 " edition (2005) .
A pharmaceutical composition can comprise a unit dose formulation, where the unit dose is a dose sufficient to have an vasodilatory effect, preferably a vasodilatory therapeutic effect. The unit dose may be a dose administered periodically in a course of treatment or suppression of a vasodilatory disorder.
Pharmaceutical compositions containing the compounds of the invention may be in any form suitable for the intended method of administration, including, for example, a solution, a suspension, or an emulsion. Liquid carriers are typically used in preparing solutions, suspensions, and emulsions. Liquid carriers contemplated for use in the practice of the present invention include, for example, water, saline, pharmaceutically acceptable organic solvent(s),
pharmaceutically acceptable oils or fats, and the like, as well as mixtures of two or more thereof. The liquid carrier may contain other suitable pharmaceutically acceptable additives such as solubilizers, emulsifiers, nutrients, buffers, preservatives, suspending agents, thickening agents, viscosity regulators, stabilizers, and the like. Suitable organic solvents include, for example, monohydric alcohols, such as ethanol, and polyhydric alcohols, such as glycols. Suitable oils include, for example, soybean oil, coconut oil, olive oil, safflower oil, cottonseed oil, and the like. For parenteral administration, the carrier can also be an oily ester such as ethyl oleate, isopropyl myristate, and the like. Compositions of the present invention may also be in the form of microparticles, microcapsules, liposomal encapsulates, and the like, as well as combinations of any two or more thereof.
Time-release or controlled release delivery systems may be used, such as a diffusion controlled matrix system or an erodible system, as described for example in: Lee,
"Diffusion-Controlled Matrix Systems", pp. 155-198 and Ron and Langer, "Erodible Systems", pp. 199-224, in "Treatise on Controlled Drug Delivery", A Kydonieus Ed. , Marcel Dekker, Inc. , New York 1992. The matrix may be, for example, a biodegradable material that can degrade spontaneously in situ and in vivo for, example, by hydrolysis or enzymatic cleavage, e.g. , by proteases. The delivery system may be, for example, a naturally occurring or synthetic polymer or copolymer, for example in the form of a hydrogel. Exemplary polymers with cleavable linkages include polyesters, polyorthoesters, polyanhydrides, polysaccharides, poly(phosphoesters), poly amides, polyurethanes, poly(imidocarbonates) and poly(phosphazenes ).
The compounds of the invention may be administered enterally, orally, parenterally, sublingually, by inhalation (e. g. as mists or sprays), rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically or physiologically acceptable carriers, adjuvants, and vehicles as desired. For example, suitable modes of administration include oral, subcutaneous, transdermal, transmucosal, iontophoretic, intravenous, intraarterial, intramuscular, intraperitoneal, intranasal (e. g. via nasal mucosa), subdural, rectal, gastrointestinal, and the like, and directly to a specific or affected organ or tissue. For delivery to the central nervous system, spinal and epidural administration, or administration to cerebral ventricles, can be used. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. The compounds are mixed with pharmaceutically acceptable carriers, adjuvants, and vehicles appropriate for the desired route of administration.
Oral administration is a preferred route of administration, and formulations suitable for oral administration are preferred formulations.
The compounds described for use herein can be administered in solid form, in liquid form, in aerosol form, or in the form of tablets, pills, powder mixtures, capsules, granules, injectables, creams, solutions, suppositories, enemas, colonic irrigations, emulsions, dispersions, food premixes, and in other suitable forms. The compounds can also be administered in liposome formulations.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in propylene glycol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols that are solid at room temperature but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents.
The invention also provides articles of manufacture and kits containing materials useful for treating, preventing, or suppressing symptoms associated with vasodilatory related conditions or disorders. The article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition having an active agent which is effective for treating, preventing, or suppressing symptoms associated with a vasodilatory disorder or with a condition associated with vasodilatory dysfunction. The active agent in the composition is one or more of the compounds of the invention. The label on the container preferably indicates that the composition is used for treating, preventing, or suppressing symptoms associated with a vasodilatory related disorder or condition, and may also indicate directions for either in vivo or in vitro use, such as those described above.
The invention also provides kits comprising any one or more of the compounds of the invention. In some embodiments, the kit of the invention comprises the container described above. In other embodiments, the kit of the invention comprises the container described above and a second container comprising a buffer. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host to which the active ingredient is administered and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, body area, body mass index (BMI), general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the type, progression, and severity of the particular disease undergoing therapy or condition to be treated. The unit dosage chosen is usually fabricated and administered to provide a defined final concentration of drug in the blood, tissues, organs, or other targeted region of the body. The effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician or skilled person.
The present invention will be further illustrated using the examples below. In the examples, reference is made to figures wherein
Figure 1: Shows the constriction responses to phenylephrine (PE) in the presence of different doses of SUL-150 (B) and SUL-151 (C). Methoxamine-induced vasoconstriction was measured with intact endothelium (D) and endothelium-denuded rings (E) in the presence of vehicle (0.1% DMSO) and two dosages (30μΜ and ΙΟΟμΜ) of
SUL-150. Data is obtained from 2-3 experiments (n=4-6 per group). Constriction in Figures IB and 1C is expressed as percentage of response to final PE addition.
Figure 2: Shows constriction responses to histamine (A) and the thromboxane agonist
U46619 (B) after pre-treatment with vehicle (0.1% DMSO) and two dosages (30μΜ and ΙΟΟμΜ) of SUL-150.
Figure 3: Shows constriction responses to phenylephrine in the presence of vehicle and three concentrations of the EGFR inhibitor AG1478 (A) and 20μΜ AG1478 with 50μΜ SUL-150 (B).
Figure 4: Shows intracellular calcium measurements in transgenic CHO cells overexpressing
(Xi adrenoceptor subtypes A (A), B (B) and D (C) after stimulation with phenylephrine in the presence of vehicle (10% DMSO), 10μΜ, 30μΜ or ΙΟΟμΜ SUL-150. Figure D shows the lack of effect of SUL-151. Figures E and F show intracellular calcium transients mediated by histamine and U46619, respectively, in HeLa cells after treatment with SUL-150.
Figure 5: Shows displacement of tritium-labelled prazosin by SUL-150 and SUL-151 in diA
adrenoceptor transgenic CHO cells. Figure 6: Shows the structural formula of the SUL-121 ((6-hydroxy-2,5,7,8- tetramethylchroman-2-yl)-(piperaziniyl)-methanone) compound. SUL-121 is a racemic 1: 1 mixture of (R)-enantiomer SUL-150 and (S)-enantiomer SUL-151. The * indicates the chiral centre of SUL-121 in the structural formula, which is at the 2 position in the chromanol group. Therefore, generally, the group of enantiomers is named the "2-R enantiomer of.
Examples Example 1:
Tissue preparation and myography in isolated porcine renal arteries
Porcine kidneys were obtained from a local slaughterhouse (Kroon Vlees, Gotenburgweg 30, 9723 TM Groningen, The Netherlands) and transported on ice in normal physiological Krebs buffer containing 120 mM NaCl, 6 mM KCl, 2.5 mM CaCl2 x 2H20, 1.2 mM MgCl2 x 6H20, 1.2 mM NaH2P04 x H20, 25 mM NaHC03 and 11.4 mM D-(+)-Glucose monohydrate (all ingredients were purchased from Merck) in ultrapure water.
The renal artery tree was dissected from the kidney, cleaned of surrounding connective tissue and cut into equally-sized ring segments (2 mm in length). In some rings, endothelium denudation was performed by gentle rubbing of the intimal surface with a paper clip. Rings were mounted in organ baths as described previously (Buikema et al., 2000). Arterial rings were washed thoroughly by replacing Krebs buffer and allowed to equilibrate for a period of 60 min under 1.4g of resting tension before they were assessed for viability by inducing 2 subsequent constrictions with KCl (60mM). Rings that failed to produce a threshold increase in diameter of ΙΟΟμιη were excluded. After washout and stabilization, rings were treated for 30 minutes by incubation with vehicle (0.1% DMSO), SUL-121, SUL-150 or SUL-151, followed by subsequent incubation with cumulative doses of phenylephrine.
Dose-dependent constriction responses to phenylephrine (10 8M - 104M) were recorded in said isolated porcine intrarenal arteries. Buffer was warmed to 37°C and aerated with 95 % 02 and 5 % C02 before use.
Example 2:
Cell culture CHO-K1 cells were stably transfected with a plasmid containing human al-AR subtypes A, B and D in separate cell lines in DMEM-F12 medium with 10% FBS, 1% penicillin- streptomycin and 200 g/mL Geneticin (G418, Invitrogen, Carlsbad, CA).
HeLa cells endogenously expressing histamine and TP receptors were grown in DMEM-F12 medium enriched with 10% FBS and 1% penicillin-streptomycin. Cells were kept in a tissue culture incubator at 37°C in 5% 02 / 95% C02 atmosphere and grown in 75cm2 non-treated cell culture flasks. Plating was performed 24 hours before measurement on black transparent- bottom 96-well plates at 20,000 cells per well density. Example 3:
Intracellular calcium assays
On the next day, CHO cells were treated with either vehicle (0.1% DMSO) or SUL-121 enantiomers for 30 min at 37°C and stimulated with a 3-fold dilution series of PE (20μΜ- ΙΟΟρΜ). [Ca2+]i was measured using the fluorescent FLIPR Calcium 6 assay kit (Molecular Devices) in immortalized CHO cells stably expressing the \ adrenoceptor.
Initially, calcium responses induced by non-cumulative concentration series of phenylephrine were investigated using fluorescent measurements in diA adrenoceptor- overexpressing CHO cells treated with SUL-150 and SUL-151 (Figure 4). Fluorescent measurement data was processed and analyzed in SoftMax Pro 7 and expressed as % of baseline AUC with a 3-fold multiplier using an average of first 10 measurement points as baseline.
The "Vehicle" used in all experiments is 0.1% DMSO solution.
Data and statistical analysis
Vascular constriction responses are expressed as percentage of final response to KC1. Data are expressed as mean + SEM. *p < 0.05.
Example 4 Induced fit molecular docking simulation
The binding of SUL-150 to the antagonist binding site on the aiA-AR, induced fit molecular docking simulation was performed, using prazosin as a reference as follows.
The primary sequence of diA adrenoceptor was obtained from UniProt database (The UniProt Consortium, 2017) using reference code P35348 and uploaded to SWISS-MODEL in order to build a homology model, resulting in 373 templates. Subsequently, template ligand codes were used to query the PDB database to obtain structural data in SMILES format, which were processed by Chemmine to detect similarities with SUL-150. The SWISS-MODEL template that contained a ligand with the highest similarity score (a D3 dopamine receptor in complex with, Eticlopride, ETQ) was used to align the diA-AR sequence onto a modelled backbone. The resulting homology model was validated by Ramachandran plot and prepared with Protein Preparation Wizard by the addition of hydrogens, bond order assignment, generation of partial charges to heteroatoms and disulfide bonds. Final refinement was performed by hydrogen bond assignment at pH 7.4 and restrained minimization at 0.3 RMSD.
Prazosin, SUL-150 and SUL-151 structural files were converted from SMILES to 3D structures using LigPrep. Protonation states were generated with Epik at pH 7.4 and small molecule energy parameters were computed using OPLS3 forcefield.
Flexible molecular docking simulation was performed using Induced Fit, part of the Schrodinger Small-Molecule Drug Discovery suite. A binding centroid was defined between residues involved in antagonist binding confirmed by mutagenesis (PHE312, PHE308 and ASP106) and ligands were docked within 15A, using an extended sampling protocol without constrains. Residues within 5A of resulting ligand poses were refined using Prime to improve ligand conformational sampling. Finally, the Scorpion server was used for the assessment and classification of small molecule-protein interactions and the final results were rendered using PyMOL 2.0. Results
Effects of SUL-150 and SUL-151 on σ.ι adrenoceptor mediated vasoconstriction
To explore the effects of the enantiomers of (6-hydroxy-2,5,7,8- tetramethylchroman-2-yl)(piperazin- l-yl)methanone (SUL-150 and SUL-151) on constriction of isolated porcine intrarenal arteries, cumulative dose response curves to the x adrenoceptor agonist phenylephrine (PE) were constructed in the presence and absence of SUL-150 and SUL-151. The results are presented in Table 1.
Table 1: LogECso values of phenylephrine-induced constriction responses in the presence
SUL-150 and SUL-151.
Phenylephrine
SUL-150 SUL-151
Vehicle -5.77+0.04
10μΜ -5.11+0.09* -5.82+0.05
30μΜ -5.06+0.06* -5.89+0.04*
ΙΟΟμΜ -4.44+0.09* -5.77+0.04
# p < 0.05 vs vehicle, * p < 0.0001 vs vehicle Whereas SUL-150 exerted a dose-dependent increase of EC50 (Figure 1 A, Table 1), we observed no significant effects after treatment with SUL-151 (Figure IB, Table 1).
Additionally, the effects of SUL-150 were investigated on stimulation with methoxamine, which is an alternative ai adrenoceptor agonist. Similar to PE, dose response curves to methoxamine were shifted rightward by SUL-150 pre-treatment (Figure 1C). Removal of the endothelium did not abrogate the effects of SUL-150 on methoxamine induced constriction (Figure ID).
Effects of SUL-150 on histamine and U46619 induced vasoconstriction
To gain insight into receptor specificity of SUL-150, the effects of SUL-150 on histamine and U46619 (a synthetic thromboxane agonist) induced constrictions were investigated (Figure 2). SUL-150 did not affect constriction responses to histamine (Table 2) and although the shift in EC50 of U46619-induced constrictions in the presence of ΙΟΟμΜ SUL-150 was statistically significant (Table 2), the small effect size led us to exclude an action of SUL-150 on thromboxane receptors.
Table 2: LogECso values of histamine and U46619-induced constriction responses in the presence of SUL-150.
Figure imgf000013_0001
* p < 0.05 versus vehicle
Effects of SUL-150 mediated through EGFR transactivation
Inhibition of EGF receptor (EGFR) transactivation is known to inhibit ai adrenoceptor mediated constrictions (REF). Therefore, we investigated the role of EGFR transactivation in SUL-150 mediated inhibition of vasoconstriction. For this, porcine intrarenal arteries were pre-treated with the EGFR blocker AG1478 (Figure 3). First, an initial measurement was performed to determine the dose of AG1478 which would cause maximal inhibition of vascular constriction induced by PE (Figure 3A). Subsequently, isolated arteries were treated with AG1478 (20μΜ) and SUL- 150 (50μΜ) and studied for PE-induced vasoconstriction. Despite maximal inhibition of EGFR transactivation by AG1478, SUL-150 still demonstrated an additional inhibitory effect on PE-mediated constriction (Figure 3B).
Effects of SUL-150 on PE-induced intracellular calcium signalling To further investigate the mechanisms through which SUL-150 inhibits ai adrenoceptor mediated contractions, PE-induced calcium transients were studied in CHO cells stably overexpressing the human ai adrenoceptor subtypes A, B and D. SUL-150 shifted dose response curves rightwards for all three ai adrenoceptor subtypes (Figure 4A, B and C, Table 3). SUL-151 did not affect calcium transients in any of the investigated ai adrenoceptor subtypes (only shown for the ai adrenoceptor A subtype in Figure 4D).
Table 3: LogECso values of phenylephrine-induced calcium influx after treatment with SUL-
150.
Figure imgf000014_0001
* p < 0.0001 versus vehicle
Effects of SUL-150 on histamine- and U46619-induced intracellular calcium signalling
To confirm specificity of SUL-150 for the ai adrenoceptor additionally histamine and U46619 induced calcium transients were studied in HeLa cells endogenously expressing human histamine Hi receptor. SUL-150 did not significantly affect histamine and U46619 induced calcium transients (Figures 4E, 4F and Table 2).
Radioligand binding assay in O.IA adrenoceptor overexpressing CHO cells
SUL-150 affected PE-induced calcium transients, indicating that the effects of
SUL-150 are upstream of calcium. We therefore explored whether SUL-150 could directly interact with the ai adrenoceptor as a receptor antagonist. For this, a displacement binding assay was performed on the (XiA adrenoceptor transgenic CHO cells using radiolabeled prazosin, an established (XiA adrenoceptor antagonist. SUL- 150 was more potent in displacing the radioligand compared to SUL-151, which displaced [7-Methoxy-3H]-prazosin only at concentrations higher than 10μΜ (Figure 5).
Induced fit molecular modelling
Prazosin coexists in two protonation forms at pH 7.4. In the protonated form, the Nl assumes a positive charge, subsequently forming a salt bridge with the negatively charged side chain of ASP106, ultimately causing this form to assume an inverted orientation relative to its non- protonated form. The quinazoline scaffold of non-protonated prazosin was docked close to TM5 to form a confocal hydrogen bond between the 6,7-methoxy groups and SER188, a hydrogen bond between furan oxygen and SER83, and between prazosin carboxamide and GLN177 side chain; van der Waals interactions with side chains of PHE86, VAL107, ILE178, PHE289, MET292, and PHE312; π-π interactions with PHE288 and PHE312; and a π-hydrogen bond interaction with the side chain carboxy group and backbone peptide carboxamide of ASP106. The proposed binding mode of non-protonated prazosin indicated interactions which were in accord with those described in the literature.
An induced fit of SUL-150 and SUL-151 demonstrated alignment of the chromane scaffold with prazosin quinazoline, 6-hydroxy groups (SUL) and 6-metoxy (prazosin) as well as over their common piperazine moiety. Residues which were involved in forming contacts with all three compounds were VAL107, ILE178, SER188, PHE288, PHE289.
Glide scores computed using the Schrodinger Small-Drug Discovery Suite were - 10.8 kcalxmol"1, -10.2 kcalxmol 1 and -9.4 kcalxmol 1 for prazosin, SUL-150 and SUL-151 respectively. Prazosin and SUL-150 formed contacts with PHE312 and ASP106 confirmed in prazosin binding by mutagenesis, whereas SUL-151 did not show interactions with these residues. Additionally, the chirality of SUL-150 enables the orientation of its carboxamide towards ASN179, effectively forming a hydrogen bond. Additional hydrogen bond was formed between its protonated N- terminal and TYR316.
Comparison of the binding site-interactions of the several SUL compounds with the binding SUL-150, and the non-binding of SUL-151 and SUL-132 and SUL-138, allowed the prediction that the now claimed SUL-compounds indeed have the binding properties claimed.

Claims

1. (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramefhylchroman-2- yl)(piperazin-l-yl)methanone; (6-hydroxy-2,5,7,8-tetramefhylchroman-2- yl)(morpholino)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide, N- (4-fluorobenzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; 6-hydroxy-N-((S)-2- hydroxy-l-phenylethyl)-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy- 2,5,7, 8-tetramethylchroman-2-carboxamide; 6-hydroxy-2,5,7,8-tetramethyl-N-(2- nitrophenyl)chroman-2-carboxamide; 6-hydroxy-2,5,7,8-tetramethyl-N-(3-nitrophenyl)chroman-2- carboxamide; N-(4-fluorophenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; N-( (R)-2-amino-2-oxo-l- phenylethyl)-6-hydroxy-2,5, 7,8-tetramethylchroman-2-carboxamide; (6-hydroxy-2,5,7,8- tetramethylchroman-2-yl)((S)-2-(hydroxymethyl )pyrrolidin-l-yl )methanone; 2-(((4- fluorobenzyl)amino)methyl)-2,5,7,8-tetramethylchroman-6-ol; 2-(((S)-2-
(hydroxymethyl)pyrrolidin-l-yl)methyl)-2,5,7,8-tetramethylchroman-6-ol; 2-((((S)-2-hydroxy-l- phenylethyl)amino)methyl)-2,5,7,8-tetramethvlchroman-6-ol; 2-(((S)-2- (hydroxymethyl)pyrrolidin-l-yl)methyl)-2,5,7,8-tetramethvlchroman-6-ol; 2-(((R-2- (hydroxymethyl)pyrrolidin-l-yl)methyl)-2,5,7,8-tetramethylchroman-6-ol; ( 6-hydroxy-5, 7- diisopropyl-2,8-dimethylchroman-2-yl)(piperazin-l-yl)methanone; l-( 6-hydroxy-2,5, 7 ,8- tetramethylchroman-2-carbonyl )-pyrrolidine-S-2-carboxvlic acid, and pharmaceutically acceptable salts thereof.
2. The (2R) enantiomeric form of a 6-chromanol derivative for use according to claim 1, wherein said 6-chromanol derivative is chosen from the group consisting of the 2R enantiomer of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone; N- (benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.
3. The (2R) enantiomeric form of a 6-chromanol derivative for use according to claim 2, wherein said 6-chromanol derivative is chosen from the group consisting of the 2R enantiomer of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and (6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone.
4. The (2R) enantiomeric form of a 6-chromanol derivative for use according to claim 3, wherein said 6-chromanol derivative is (R)(6-hydroxy-2,5,7,8-tetramefhylchroman-2- yl)(piperazin-l-yl)methanone and pharmaceutically acceptable salts thereof.
5. The (2R) enantiomeric form of a 6-chromanol derivative for use according to any one of the claims 1 to 4, wherein said vasoconstriction related disorder is selected from the group consisting of pulmonary hypertension, portal hypertension, vasospastic diseases, Raynaud's disease, acrocyanosis, livedo reticularis, post-traumatic dystrophy, occlusive diseases associated with inflammation, (pre)eclampsia, and Buerger's disease.
6. The (2R) enantiomeric form of a 6-chromanol derivative for use according to any one of the claims 1 to 5, wherein said prophylaxis or treatment of vasoconstriction related disorders or conditions is mediated by inhibition of the al adrenoceptor.
7. The (2R) enantiomeric form of a 6-chromanol derivative for use according to claim 6, wherein said prophylaxis or treatment of vasoconstriction related disorders or conditions is selected from pulmonary arterial hypertension, heart failure with preserved ejection fraction and cardiac hypertrophy and fibrosis.
8. The (2R) enantiomeric form of a 6-chromanol derivative, wherein said 6- chromanol derivative is chosen from the group consisting of the 2R enantiomer of (6-hydroxy- 2,5,7, 8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof .
9. The (2R) enantiomeric form of a 6-chromanol derivative of claim 8, wherein the derivative is (2R)(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone and pharmaceutically acceptable salts thereof.
10. The compound of claim 8 or 9 for use as a medicament.
11. The compound for use according to any one of claims 1-7 and 10, wherein the compound is used in an amount sufficient to achieve a concentration of 1 μΜ or higher.
12. The compound for use according to claim 11, wherein the compound is used in an amount sufficient to achieve a concentration of about 10 μΜ or higher.
13. Pharmaceutical dosage form comprising the compound for use according to any one of claims 1-7 and 10-12, wherein the compound is present in an amount of 10 mg - 500 mg, preferably 100 - 500 mg.
14. Pharmaceutical dosage form according to claim 13, wherein the dosage form is a solid, preferably solid oral dosage form.
PCT/EP2018/072735 2017-08-25 2018-08-23 Medicaments for the treatment of vasoconstriction related diseases or disorders WO2019038361A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18769288.4A EP3672593B1 (en) 2017-08-25 2018-08-23 Medicaments for the treatment of vasoconstriction related diseases or disorders
US16/640,785 US12156862B2 (en) 2017-08-25 2018-08-23 Medicaments for the treatment of vasoconstriction related diseases or disorders
ES18769288T ES3013118T3 (en) 2017-08-25 2018-08-23 Medicaments for the treatment of vasoconstriction related diseases or disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NLN2019446 2017-08-25
NL2019446 2017-08-25
NLN2020985 2018-05-24
NL2020985 2018-05-24

Publications (1)

Publication Number Publication Date
WO2019038361A1 true WO2019038361A1 (en) 2019-02-28

Family

ID=63579308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/072735 WO2019038361A1 (en) 2017-08-25 2018-08-23 Medicaments for the treatment of vasoconstriction related diseases or disorders

Country Status (4)

Country Link
US (1) US12156862B2 (en)
EP (1) EP3672593B1 (en)
ES (1) ES3013118T3 (en)
WO (1) WO2019038361A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022058620A1 (en) * 2020-09-21 2022-03-24 Sulfateq B.V. Chromanol compounds for treatment of heart failure
WO2023163596A1 (en) * 2022-02-28 2023-08-31 Sulfateq B.V. Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110933933B (en) * 2018-07-18 2022-12-27 温州医科大学 Method for treating myopia and application of prepared medicine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014098586A1 (en) 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells
WO2015193365A1 (en) 2014-06-17 2015-12-23 Sulfateq B.V. 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
WO2016188766A1 (en) 2015-05-22 2016-12-01 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014098586A1 (en) 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells
EP2935232A1 (en) * 2012-12-19 2015-10-28 Sulfateq B.V. Compounds for protection of cells
WO2015193365A1 (en) 2014-06-17 2015-12-23 Sulfateq B.V. 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
WO2016188766A1 (en) 2015-05-22 2016-12-01 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2003, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA
"Remington's Pharmaceutical Sciences", 1991, MACK PUB. CO.
"Treatise on Controlled Drug Delivery", 1992, MARCEL DEKKER, INC.
BING HAN ET AL: "The anti-inflammatory and bronchodilating properties of the novel pharmacological compound Sul-121", INTERNET CITATION, 24 April 2015 (2015-04-24), pages 10, XP002742182, Retrieved from the Internet <URL:http://www.nvfarmaco.nl/assets/docs/Abstracts_NVF_Voorjaarsdag_2015.pdf> [retrieved on 20150714] *
BING HAN ET AL: "The novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease", SCIENTIFIC REPORTS, vol. 6, no. 1, 27 May 2016 (2016-05-27), XP055526648, DOI: 10.1038/srep26928 *
LEE, DIFFUSION-CONTROLLED MATRIX SYSTEMS, pages 155 - 198
RON; LANGER, ERODIBLE SYSTEMS, pages 199 - 224

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022058620A1 (en) * 2020-09-21 2022-03-24 Sulfateq B.V. Chromanol compounds for treatment of heart failure
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
CN116322661A (en) * 2020-09-21 2023-06-23 萨尔法泰克有限公司 Chromanol compounds for the treatment of heart failure
WO2023163596A1 (en) * 2022-02-28 2023-08-31 Sulfateq B.V. Chromanol compounds for treatment or prophylaxis of ageing-associated disorders
NL2031091B1 (en) * 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders

Also Published As

Publication number Publication date
EP3672593A1 (en) 2020-07-01
EP3672593B1 (en) 2024-12-18
US20210128523A1 (en) 2021-05-06
ES3013118T3 (en) 2025-04-11
US12156862B2 (en) 2024-12-03
EP3672593C0 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
US5212176A (en) R(+)-terazosin
AU2010241513B9 (en) Use of brimonidine for preventing and reducing the severity of stress-associated conditions
US12156862B2 (en) Medicaments for the treatment of vasoconstriction related diseases or disorders
HUE032948T2 (en) Opioid receptor ligands and methods for their use and production
JP2003530429A (en) Methods and compositions for modulating alpha adrenergic receptor activity
SK287828B6 (en) 5-Halo-tryptamine derivatives used as ligands of 5-HT6 and/or 5-HT7 serotonin receptors
JPWO2020050253A1 (en) Drugs for diabetic peripheral neuropathy
IE51736B1 (en) Imidazoline derivative
KR101747486B1 (en) Therapeutic agent for pain
CN103989682B (en) Therapy with centhaquin
US11730741B2 (en) 6-chromanol derivatives for use as a medicament
WO2006035617A1 (en) α2 RECEPTOR BLOCKING AGENT CONTAINING INDOLE DERIVATIVE AS ACTIVE INGREDIENT AND VASODILATOR
US20070259945A1 (en) Method for treating pain
EP4218818A1 (en) Alpha-2 adrenergic receptor antagonist
US20020040018A1 (en) Subtype selective melatonergics
KR20110071079A (en) Pharmaceutical Composition for Novel Treatment of Invasive Soluble Pain
KR20210040228A (en) Anti-histamine compounds, pharmaceutical compositions and medical-use thereof
WO2025096783A1 (en) Enhancers of particulate guanylyl cyclase receptor b
JPWO2003068263A1 (en) Antihypertensive drug
JPH11506094A (en) 3 (2H) -pyridazinone derivatives and pharmaceutical compositions containing the compounds
WO2002076399A2 (en) YOHIMBINE DIMERS EXHIBITING BINDING SELECTIVITES FOR α2 ADRENERGIC RECEPTORS
KR20190103385A (en) 4,4-diphenylpiperidine compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition and use thereof
WO2004071433A2 (en) Methods of treating disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18769288

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018769288

Country of ref document: EP

Effective date: 20200325

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载